# US 2011/0311578 A1 · Recombinant inactivated viral vector vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0311578 A1
- Document ID: US20110311578A1
- Status: Published application
- Kind: A1
- Application number: 13/111,759
- Filed: 2011-05-19
- Published: 2011-12-22
- Earliest claimed: 2008-11-19
- Assignees: Laboratorio Avi-Mex, S.A. De C.V.
- Inventors: Bernardo LOZANO-DUBERNARD; David Sarfati-Mizrahi; Jesús Alejandro Suárez-Martínez; Manuel Joaquin Gay-Gutierrez; Ernesto Soto-Priante
- Web page: https://patentgrep.com/patent/US20110311578A1

## CPC

- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/12: Viral antigens
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/20: for DNA viruses
- A61P 37/04: Immunostimulants
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2710/10043: viral genome or elements thereof as genetic vector
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18143: viral genome or elements thereof as genetic vector
- C12N 2760/18163: by chemical treatment
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2790/00034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A vaccine is described, comprising an inactivated viral vector having inserted an exogenous nucleotide sequence coding for a disease of concern; and, a pharmaceutically acceptable vehicle, adjuvant or excipient, which provides due protection against the disease of concern by using a viral vector titer similar to that required for an active-virus vaccine based on the same viral vector. Mainly, viral vectors of paramixovirus or adenovirus are described.

## Claims

### Claim 1

A recombinant vaccine comprising a viral vector and a pharmaceutically acceptable vehicle, adjuvant or excipient, characterized in that the viral vector is inactivated and has an exogenous nucleotide sequence inserted that codifies for an antigen of a disease of concern, wherein the vaccine is effective against at least the disease of concern.

### Claim 2 (depends on 1)

A recombinant vaccine, according to claim 1, further characterized in that the exogenous nucleotide sequence codifies for an antigen selected from influenza, infectious laryngotracheitis, infectious bronchitis, bursa of Fabricius' infection (Gumboro), hepatitis, viral rhinotracheitis, infectious coryza, Mycoplasma hyopneumonieae, pasteurellosis, Porcine Respiratory and Reproductive Syndrome (PRRS), circovirus, bordetellosis or parainfluenza.

### Claim 3 (depends on 2)

A recombinant vaccine, according to claim 2, further characterized in that the exogenous nucleotide sequence consists of the gene coding for hemagglutinin (HA) of the avian influenza virus.

### Claim 4 (depends on 3)

A recombinant vaccine, according to claim 3, further characterized in that the gene coding for hemagglutinin (HA) is selected from at least one of the hemagglutinin (HA) subtypes H1, H2, H3, H5, H6, H7 or H9 of the avian influenza virus.

### Claim 5 (depends on 4)

A recombinant vaccine, according to claim 4, further characterized in that the gene coding for the hemagglutinin (HA) is the subtype H5.

### Claim 6 (depends on 1)

A recombinant vaccine, according to claim 1, further characterized in that the viral vector is selected from adenovirus or paramixovirus.

### Claim 7 (depends on 6)

A recombinant vaccine, according to claim 6, further characterized in that the viral vector is selected from paramixovirus.

### Claim 8 (depends on 7)

A recombinant vaccine, according to claim 7, further characterized in that the paramixovirus is the Newcastle disease virus.

### Claim 9 (depends on 8)

A recombinant vaccine, according to claim 8, further characterized in that the Newcastle disease virus is selected from LaSota, Ulster, QV4, B1, CA 2002, Roakin, Komarov, Clone 30, or VGGA strains, or strains from the Newcastle disease genetic groups I to V.

### Claim 10 (depends on 6)

A recombinant vaccine, according to claim 6, further characterized in that the viral vector is selected from adenovirus.

### Claim 11 (depends on 10)

A recombinant vaccine, according to claim 10, further characterized in that the adenovirus is selected from avian or porcine adenovirus.

### Claim 12 (depends on 11)

A recombinant vaccine, according to claim 11, further characterized in that the adenovirus is an avian adenovirus type 9.

### Claim 13 (depends on 11)

A recombinant vaccine, according to claim 11, further characterized in that the adenovirus is a porcine adenovirus type 5.

### Claim 14 (depends on 1)

A recombinant vaccine, according to claim 1, further characterized in that the pharmaceutically acceptable vehicles for the vaccine are preferably aqueous solutions or emulsions.

### Claim 15 (depends on 14)

A recombinant vaccine, according to claim 14, further characterized in that a water-oil emulsion is used as vehicle.

### Claim 16 (depends on 1)

A recombinant vaccine, according to claim 1, further characterized in that the required titer for the viral vector is similar to that required for a recombinant active-virus vaccine.

### Claim 17 (depends on 16)

A recombinant vaccine, according to claim 16, further characterized in that the virus concentration required to achieve the antigenic response is between 102 and 1010 DI50%/ml.

### Claim 18 (depends on 7)

A recombinant vaccine, according to claim 7, further characterized in that the virus concentration required to achieve the antigenic response is between 104 and 1010 DIEP50%/ml.

### Claim 19 (depends on 18)

A recombinant vaccine, according to claim 18, further characterized in that the virus concentration is between 108 and 109 DIEP50%/0.5 ml per chicken when the vaccine is prepared to be administered in chickens.

### Claim 20 (depends on 19)

A recombinant vaccine, according to claim 19, further characterized in that the vaccine has 108.5 DIEP50%/0.5 ml per chicken.

### Claim 21 (depends on 10)

A recombinant vaccine, according to claim 10, further characterized in that the virus concentration required to achieve the antigenic response is between 102 and 108 DIEP50%/ml.

### Claim 22 (depends on 1)

A recombinant vaccine, according to claim 1, further characterized in that the virus concentration required to achieve the antigenic response is the vaccine is prepared to be subcutaneously or intramuscularly administered.

### Claim 23

A vaccination method against animal's diseases, characterized in that it comprises administering to an animal a recombinant vaccine comprising an inactivated viral vector having inserted an exogenous nucleotide sequence coding for an antigen of said disease.

### Claim 24 (depends on 23)

A vaccination method against animal's diseases, according to claim 23, further characterized in that a recombinant vaccine is additionally administered to the animal, comprising an active viral vector identical to the inactivated viral vector, having an exogenous nucleotide sequence inserted coding for an antigen of said disease.

### Claim 25

An identification method between infected animals and vaccinated animals, useful for the control and eradication of diseases, characterized in that it comprises:
a) subjecting to a first antibodies detection method, at least one sample of at least one animal having received a recombinant vaccine of inactivated viral vector having inserted an exogenous nucleotide sequence coding for an antigen of a disease caused by a pathogen, to detect if there are antibodies present in said sample, corresponding to said antigen;
b) subjecting to a second antibodies detection method, at least one sample from the same animal which sample was subjected to the first antibodies detection method, to detect if there are antibodies present in said sample corresponding to the pathogen causing the disease;
c) determining if the animal is infected or vaccinated from the results of the first and second antibodies detection methods.
